Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.41 |
| ▸ | LSS | P48449 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | KLK1 | P06870 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6735703 | 0.92 | LSS (0.47) | F10LSSATMALDH1A1SLC6A7 | |
| SCHEMBL6725963 | 0.88 | CA12 (0.42) | F10SLC6A7SLC6A3KLK1LMNA | |
| SCHEMBL6725145 | 0.87 | F10 (0.44) | F10SLC6A7SLC6A3LMNAL3MBTL1 | |
| SCHEMBL6730431 | 0.86 | LSS (0.53) | F10LSSATMALDH1A1SLC6A7 | |
| SCHEMBL6730433 | 0.85 | LSS (0.54) | F10LSSATMALDH1A1SLC6A7 | |
| SCHEMBL6725445 | 0.78 | F10 (0.35) | F10ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL6734646 | 0.77 | F10 (0.45) | F10SLC6A7SLC6A3KLK1LMNA | |
| SCHEMBL6725451 | 0.77 | F10 (0.36) | F10FNTAFNTBLMNAL3MBTL1 | |
| SCHEMBL6730095 | 0.75 | SLC6A7 (0.47) | F10LSSSLC6A7SLC6A3LMNA | |
| SCHEMBL5733741 | 0.73 | F10 (0.59) | F10ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | F10 19/4885LSS 1745/4885ATM 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.